{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:37:34Z","timestamp":1785465454292,"version":"3.56.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>We investigated the value of ascites and serial plasma circulating tumor DNA (ctDNA) for predicting response to hyperthermic intraperitoneal chemotherapy (HIPEC), monitoring tumor burden, and predicting prognosis in patients with peritoneal carcinomatosis (PC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Experimental Design<\/jats:title><jats:p>In this observational study, 19 patients with PC were enrolled. Serial plasma ctDNA was analyzed using next-generation sequencing. The molecular tumor burden index (mTBI) was used to detect ctDNA, and concurrent changes in the dominant clone variant allele frequency (VAF) and common tumor markers were used as controls. The correlation between ascites and plasma ctDNA comutated genes was expressed by VAF. The overall response rate (complete response + partial response) after HIPEC was determined. Ascites progression-free survival (PFS) and overall survival (OS) were determined, and potential correlations between these outcomes and change in mTBI (\u25b3mTBI), change in sum-VAF (\u25b3sum-VAF), dominant close VAF, and tumor markers were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall response rate at 1 month after HIPEC was 100%. The \u25b3mTBI (r = 0.673; P = 0.023) and \u25b3sum-VAF (r = 0.945; P &amp;lt;0.001) were significantly positively correlated with ascites PFS; these correlations were stronger than those of the dominant clone VAF (r = 0.588; P = 0.057) and tumor markers in the same period (r =0.091; P = 0.790). Patients with a low baseline mTBI (&amp;lt;0.67) demonstrated significantly longer ascites PFS (P = 0.003; HR = 0.157; 95% CI: 0.046\u20130.540) and OS (P = 0.017; HR = 0.296; 95% CI: 0.109\u20130.804) than those with a high baseline mTBI (\u22650.67). Consistent mutations were detected in plasma and ascites (r = 0.794; P = 0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A real-time serial plasma ctDNA assay accurately reflected tumor burden. The \u25b3mTBI and \u25b3sum-VAF can be used as predictors of HIPEC efficacy in patients with PC. A high baseline mTBI may be a negative risk factor for prognosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.791418","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T06:26:00Z","timestamp":1643091960000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Ascites and Serial Plasma Circulating Tumor DNA for Predicting the Effectiveness of Hyperthermic Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinomatosis"],"prefix":"10.3389","volume":"12","author":[{"given":"Xiaolin","family":"Pu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s10434-001-0632-1","article-title":"Outcome of Palliative Operations for Malignant Bowel Obstruction in Patients With Peritoneal Carcinomatosis From Nongynecological Cancer","volume":"8","author":"Blair","year":"2001","journal-title":"Ann Surg Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2168.2002.02274.x","article-title":"Peritoneal Carcinomatosis From Colorectal Cancer","volume":"89","author":"Jayne","year":"2002","journal-title":"Br J Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O","article-title":"Peritoneal Carcinomatosis From non-Gynecologic Malignancies: Results of the EVOCAPE 1 Multicentric Prospective Study","volume":"88","author":"Sadeghi","year":"2000","journal-title":"Cancer"},{"key":"B4","article-title":"Clinical Delivery System for Intraperitoneal Hyperthermic Chemotherapy","volume":"40","author":"Spratt","year":"1980","journal-title":"Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical Research Methodologies in Diagnosis and Staging of Patients With Peritoneal Carcinomatosis","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.9285","article-title":"Peritoneal Colorectal Carcinomatosis Treated With Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective Analysis of 523 Patients From a Multicentric French Study","volume":"28","author":"Elias","year":"2010","journal-title":"J Clin Oncol"},{"key":"B7","first-page":"67","article-title":"Soluble Normal and Mutated DNA Sequences From Single-Copy Genes in Human Blood","volume":"3","author":"Sorenson","year":"1994","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/511524a","article-title":"Cancer Biomarkers: Written in Blood","volume":"511","author":"Yong","year":"2014","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3109\/09553002.2014.892229","article-title":"Cancer Biomarker Discovery: Current Status and Future Perspectives","volume":"90","author":"M\u00e4bert","year":"2014","journal-title":"Int J Radiat Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9453","article-title":"Circulating Tumor DNA: A Promising Biomarker in the Liquid Biopsy of Cancer","volume":"7","author":"Cheng","year":"2016","journal-title":"Oncotarget"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid Biopsies Come of Age: Towards Implementation of Circulating Tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nature12065","article-title":"Non-Invasive Analysis of Acquired Resistance to Cancer Therapy by Sequencing of Plasma DNA","volume":"497","author":"Murtaza","year":"2013","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0436","article-title":"Cell-Free DNA From Ascites and Pleural Effusions: Molecular Insights Into Genomic Aberrations and Disease Biology","volume":"16","author":"Husain","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/15384047.2018.1504720","article-title":"Next-Generation Sequencing Reveals Mutational Accordance Between Cell-Free DNA From Plasma, Malignant Pleural Effusion and Ascites and Directs Targeted Therapy in a Gastric Cancer Patient","volume":"20","author":"Zhou","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2019.700","article-title":"Clinical Implications of Circulating Tumor DNA From Ascites and Serial Plasma in Ovarian Cancer","volume":"52","author":"Han","year":"2020","journal-title":"Cancer Res Treat"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the Evolution of Non-Small-Cell Lung Cancer","volume":"376","author":"Jamal-Hanjani","year":"2017","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"8760","DOI":"10.1038\/ncomms9760","article-title":"Multifocal Clonal Evolution Characterized Using Circulating Tumour DNA in a Case of Metastatic Breast Cancer","volume":"6","author":"Murtaza","year":"2015","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-021-01089-z","article-title":"Postoperative Circulating Tumor DNA as Markers of Recurrence Risk in Stages II to III Colorectal Cancer","volume":"14","author":"Chen","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3616","article-title":"Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer","volume":"5","author":"Tie","year":"2019","journal-title":"JAMA Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0512","article-title":"Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0528","article-title":"Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer","volume":"5","author":"Reinert","year":"2019","journal-title":"JAMA Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2204","article-title":"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Combined Treatment of Locally Advanced and Intraperitonealy Disseminated Gastric Cancer: A Retrospective Cooperative Central-Eastern European Study","volume":"8","author":"Yarema","year":"2019","journal-title":"Cancer Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07450-4","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer With Peritoneal Carcinomatosis: Multicenter Study of Spanish Group of Peritoneal Oncologic Surgery (GECOP)","volume":"26","author":"Manzanedo","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4251\/wjgo.v2.i2.85","article-title":"Multidisciplinary Therapy for Treatment of Patients With Peritoneal Carcinomatosis From Gastric Cancer","volume":"2","author":"Yonemura","year":"2010","journal-title":"World J Gastrointest Oncol"},{"key":"B25","article-title":"Continuous Hyperthermic Peritoneal Perfusion for Peritoneal Dissemination of Gastric Cancer","volume":"45","author":"Akiyama","year":"1998","journal-title":"Hepatogastroenterology"},{"key":"B26","article-title":"Clinical Evaluation of Intraperitoneal Hyperthermic Perfusion in Far-Advanced Gastric Cancer","volume":"16","author":"Kiuchi","year":"1989","journal-title":"Gan To Kagaku Ryoho"},{"key":"B27","article-title":"Relationship Between Histopathological Findings and Recurrent Pattern or Prognosis After Combined Treatment With Surgery and Intraperitoneal Hyperthermic Chemotherapy for Patients With an Advanced Gastric Cancer","volume":"4","author":"Fujimoto","year":"1992","journal-title":"Reg Cancer Treat"},{"key":"B28","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/BF01675656","article-title":"Hyperthermo-Chemotherapy Combined With Cytoreductive Surgery for the Treatment of Gastric Cancer With Peritoneal Dissemination","volume":"15","author":"Yonemura","year":"1991","journal-title":"World J Surg"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v16.i15.1901","article-title":"Chemotherapy With Laparoscope-Assisted Continuous Circulatory Hyperthermic Intraperitoneal Perfusion for Malignant Ascites","volume":"16","author":"Ba","year":"2010","journal-title":"World J Gastroenterol"},{"key":"B30","first-page":"76","article-title":"Combined Treatment With Surgery and Intraperitoneal Hyperthermic Perfusion (IPHP) for Far-Advanced Gastrointestinal Cancer With Peritoneal Seeding","volume":"16","author":"Fujimoto","year":"1989","journal-title":"Acta Med Austriaca"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2012.06.009","article-title":"Ascites and Malnutrition are Predictive Factors for Incomplete Cytoreductive Surgery for Peritoneal Carcinomatosis From Gastric Cancer","volume":"205","author":"Benizri","year":"2013","journal-title":"Am J Surg"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920981351","article-title":"Liquid Biopsy in Peritoneal Fluid and Plasma as a Prognostic Factor in Advanced Colorectal and Appendiceal Tumors After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy","volume":"12","author":"L\u00f3pez-Rojo","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.110","article-title":"Liquid Biopsy: Monitoring Cancer-Genetics in the Blood","volume":"10","author":"Crowley","year":"2013","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.791418\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T06:26:13Z","timestamp":1643091973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.791418\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":33,"alternative-id":["10.3389\/fonc.2022.791418"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.791418","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,25]]},"article-number":"791418"}}